Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944655 | 0.94 | MEN1 (0.45) | MEN1CYP2C9KMT2AAKR1C1DPP4 | |
| SCHEMBL15659683 | 0.92 | HDAC4 (0.44) | MEN1CYP2C9KMT2AAKR1C1HDAC4 | |
| SCHEMBL15656775 | 0.92 | HDAC4 (0.44) | MEN1CYP2C9KMT2AAKR1C1HDAC4 | |
| SCHEMBL13853045 | 0.89 | OPRM1 (0.41) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 | |
| SCHEMBL11489569 | 0.86 | MEN1 (0.50) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 | |
| SCHEMBL29883511 | 0.84 | MEN1 (0.48) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 | |
| SCHEMBL9683265 | 0.81 | GRIN1 (0.39) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 | |
| SCHEMBL12893199 | 0.80 | OPRM1 (0.50) | KMT2AALDH1A1OPRM1OPRL1 | |
| SCHEMBL9682670 | 0.76 | ALDH1A1 (0.43) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 | |
| SCHEMBL7308988 | 0.75 | CYP2C9 (0.44) | MEN1CYP2C9KMT2AAKR1C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118142-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2023-04-20 | — | — | US | disclosed |
| EP-4106754-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL Business PLC (GB) | 2022-12-28 | — | — | EP | disclosed |
| EP-2735581-B1 | COMPOSITION AND POLYMER | ASAHI CHEMICAL IND (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-9738757-B2 | Composition and polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-20160222168-A1 | Composition and Polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-08-04 | — | — | US | disclosed |
| US-9334371-B2 | Composition and polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-05-10 | — | — | US | disclosed |
| EP-2735581-A1 | COMPOSITION AND POLYMER | Asahi Kasei Chemicals Corporation (JP) | 2014-05-28 | — | — | EP | disclosed |
| US-20140121293-A1 | Composition and Polymer | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-05-01 | — | — | US | disclosed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | MEN1 686/4885CYP2C9 1077/4885KMT2A 2151/4885 |
| US-20230118142-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | LPO, AOX1, MPO | MEN1 3756/4885CYP2C9 3853/4885KMT2A 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.